ReVacc Scientific P63R98 | VSV-Pseudovirus_SARS-CoV-2 Omicron Strain BA.4/5 Spike with luciferase reporter

品名：VSV-Pseudovirus_SARS-CoV-2 Omicron Strain BA.4/5 Spike with luciferase reporter

货号：P63R98

品牌：ReVacc Scientific

规格：200 μl; 1000 μl

产品描述

Organism：SARS-Related Coronavirus 2 (virus caused COVID-19), Omicron BA.4 and BA.5 variant.

This pseudotyped virus uses recombinant vesicular stomatitis virus (rVSV) to carry spike protein of SARS-CoV-2 (GenBank: MN908947) with multiple mutations initially identified in variant of Omicron BA.4/5 (BA.4 and BA.5 variants share the same Spike mutations), including: T19I, LPP24-26del, A27S, del69/70, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K. The spike protein has a 18-aa cytoplasmic tail truncation for optimal infection. As pseudovirus infectivity of rVSV without its original G is restricted to a single round of replication, the pseudotypes can be handled using BSL-2 containment practices. Infection of cells with this pseudotyped virus carrying luciferase reporter results in high level luciferase activity. See our titration result showing that the starting 2-fold diluted pseudovirus generates signal over 100,000-fold higher than uninfected control (cell alone as background in blue). We also evaluated the neutralizing activity of one own S2-specific antibody RV6, a published antibody COVA1-16 and commercial antibody LY-CoV1404 (bebtelovimab) by using this pseudotyped virus. Both RV6 and COVA1-16 antibodies showed much weaker neutralizing activity against this variant than other variants, and did not reach 100% neutralizing activity at highest concentration. LY-CoV1404 (bebtelovimab) shows potent neutralizing titer (IC50 = 0.87 ng/ml), consistent with a report by others (Cao, Y. et al. Nature 602, 657–663 (2022)). See figure.